EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Epigenomic control of immunity: from mechanisms to therapeutic targets in inflammatory bowel diseases

Han-Yu Shih, Giuseppe Sciumè, Yohei Mikami iD

International Immunology · 2025

DOI: 10.1093/intimm/dxaf039 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Immunology, 2025. Verfasst von Han-Yu Shih und 2 weiteren Autor:innen. Beteiligte Einrichtung: Neuro-Immune Regulome Unit, National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Epigenesis, Genetic, Epigenomics, Immunity. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 134 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science, JSPS Grant-in-Aid for Transformative Research Areas, Grant-in-Aid for Challenging Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This review presents an overview of the emerging roles of epigenomic regulation in immune cell function, with a particular focus on its relevance in inflammatory bowel diseases (IBD). Epigenetic mechanisms, including DNA methylation, histone modification, chromatin remodeling, and non-coding RNAs, are essential in directing immune cell development, activation, and lineage commitment. Advances in genomics and epigenomics have highlighted the dynamic nature of gene regulation as the cornerstone of immune homeostasis and adaptability. We summarize recent insights into enhancer dynamics, three-dimensional chromatin architecture, transcription factor signaling, and microRNA (miRNA)-mediated regulation that reshape our understanding of immune-mediated diseases. These findings not only deepen our knowledge of disease pathogenesis but also offer promising targets for therapeutic intervention. In this context, miRNAs have emerged as key post-transcriptional regulators with significant diagnostic and therapeutic potential for IBD. The field of immune epigenomics is advancing rapidly, offering powerful tools for dissecting complex immune responses and guiding the development of precise therapies for chronic inflammatory conditions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Inflammatory Bowel DiseasesEpigenesis, GeneticEpigenomicsImmunityHumansAnimalsMicroRNAsDNA Methylation

Stichwörter der Autor:innen

Crohn’s diseasechromatin accessibilityepigenomicsulcerative colitis

Substanzen

MicroRNAs

Autor:innen und Institutionen

  • Neuro-Immune Regulome Unit, National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA.
  • National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA.
  • Department of Molecular Medicine, Sapienza University of Rome, Rome 00161, Italy.
  • Laboratory Affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Rome 00161, Italy.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.

ORCID-Profile: Yohei Mikami

Förderung

  • Japan Society for the Promotion of Science
  • JSPS Grant-in-Aid for Transformative Research Areas
  • Grant-in-Aid for Challenging Research
  • Japan Science and Technology Agency FOREST
  • Ono Pharma Oncology, Immunology, Neurology Research Foundation; and Keio University Medical Fund
  • Intramural NIH HHS

Zitieren

APA

Shih, H. Y., Sciumè, G., & Mikami, Y. (2025). Epigenomic control of immunity: from mechanisms to therapeutic targets in inflammatory bowel diseases. International Immunology. https://doi.org/10.1093/intimm/dxaf039

Vancouver

Shih HY, Sciumè G, Mikami Y. Epigenomic control of immunity: from mechanisms to therapeutic targets in inflammatory bowel diseases. International Immunology. 2025. doi:10.1093/intimm/dxaf039

BibTeX
@article{Shih2025,
  author = {Shih, Han-Yu and Sciumè, Giuseppe and Mikami, Yohei},
  title = {Epigenomic control of immunity: from mechanisms to therapeutic targets in inflammatory bowel diseases},
  journal = {International Immunology},
  year = {2025},
  doi = {10.1093/intimm/dxaf039}
}
Kostenlos starten →